Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

Contact Supplier

Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

$ API Reference Price

DEVELOPMENTS

10 Drugs in Development

10 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: C188-9, 432001-19-9, Tti-101, Stat3 inhibitor tti-101, Kz3dld11rq, C-188-9

Molecular Formula

C₂₇H₂₁NO₅S

Molecular Weight

471.5 g/mol

InChI Key

QDCJDYWGYVPBDO-UHFFFAOYSA-N

FDA UNII

KZ3DLD11RQ

STAT3 Inhibitor C-188-9 is an orally bioavailable, binaphthol-sulfonamide-based inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, the STAT3 inhibitor C-188-9 specifically targets and binds to the phosphotyrosyl peptide binding site within the Src homology 2 (SH2) domain of STAT3. This inhibits the Janus kinase (JAK)-mediated tyrosine phosphorylation and activation of STAT3. This impedes nuclear translocation of STAT3, prevents STAT3 binding to responsive gene promoters and blocks STAT3-mediated regulation of gene expression. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.

1 2D Structure

TTI-101

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide

2.1.2 InChI

InChI=1S/C27H21NO5S/c1-33-18-11-13-19(14-12-18)34(31,32)28-24-16-23(27(30)22-9-5-4-8-21(22)24)26-20-7-3-2-6-17(20)10-15-25(26)29/h2-16,28-30H,1H3

2.1.3 InChI Key

QDCJDYWGYVPBDO-UHFFFAOYSA-N

2.1.4 Canonical SMILES

COC1=CC=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C4=C(C=CC5=CC=CC=C54)O

2.2 Other Identifiers

2.2.1 UNII

KZ3DLD11RQ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. C188-9 Compound

2. N-(4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl)-4-methoxybenzenesulfonamide

3. Stat3 Inhibitor Tti-101

4. Tti-101

2.3.2 Depositor-Supplied Synonyms

1. C188-9

2. 432001-19-9

3. Tti-101

4. Stat3 Inhibitor Tti-101

5. Kz3dld11rq

6. C-188-9

7. Stat3 Inhibitor C188-9

8. Tti101

9. Benzenesulfonamide, N-(1',2-dihydroxy(1,2'-binaphthalen)-4'-yl)-4-methoxy-

10. N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl]-4-methoxybenzenesulfonamide

11. N-(4-hydroxy-3-(2-hydroxynaphthalen-1-yl)naphthalen-1-yl)-4-methoxybenzenesulfonamide

12. Unii-kz3dld11rq

13. Mls006011646

14. Chembl3392776

15. Schembl16394007

16. Tti-101 [who-dd]

17. N-(1b

18. Bcp28881

19. Ex-a1961

20. Zinc1154831

21. S8605

22. Ccg-269459

23. Ncgc00262829-02

24. Ac-32659

25. Bs-17257

26. Smr004703404

27. Hy-112288

28. Cs-0044737

29. Eu-0081697

30. A16804

31. C75162

32. Ab00117290-01

33. C 188-9

34. N-[4-hydroxy-3-(2-hydroxy-1-naphthyl)-1-naphthyl]-4-methoxy-1-benzenesulfonamide

2.4 Create Date

2005-07-10

3 Chemical and Physical Properties

Molecular Formula	C₂₇H₂₁NO₅S
Molecular Weight	471.5 g/mol
XLogP3	5.8
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	5
Exact Mass	471.11404394 g/mol
Monoisotopic Mass	471.11404394 g/mol
Topological Polar Surface Area	104 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	776
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

TTI-101 Manufacturers

A TTI-101 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of TTI-101, including repackagers and relabelers. The FDA regulates TTI-101 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. TTI-101 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

TTI-101 Suppliers

A TTI-101 supplier is an individual or a company that provides TTI-101 active pharmaceutical ingredient (API) or TTI-101 finished formulations upon request. The TTI-101 suppliers may include TTI-101 API manufacturers, exporters, distributors and traders.

TTI-101 GMP

TTI-101 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of TTI-101 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right TTI-101 GMP manufacturer or TTI-101 GMP API supplier for your needs.

TTI-101 CoA

A TTI-101 CoA (Certificate of Analysis) is a formal document that attests to TTI-101's compliance with TTI-101 specifications and serves as a tool for batch-level quality control.

TTI-101 CoA mostly includes findings from lab analyses of a specific batch. For each TTI-101 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

TTI-101 may be tested according to a variety of international standards, such as European Pharmacopoeia (TTI-101 EP), TTI-101 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (TTI-101 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Find TTI-101 manufacturers, exporters & distributors on PharmaCompass

TTI-101

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

DEVELOPMENTS

10 Drugs in Development

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 5,070

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

10DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

TTI-101 Manufacturers

TTI-101 Suppliers

TTI-101 GMP

TTI-101 CoA

What are you looking for?